 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Sage Therapeutics
SAGE
conference date: November 5, 2020
Sage Therapeutics' Deal With Biogen Should Revive It [December 11, 2020 at Seeking Alpha]
Click on summary links for quarterly earnings results, news, and management commentary. I am covering it because I own stock in Biogen, which is becoming a collaborator and investor.
| 2020 | |||
| Sage Therapeutics Q3 2020 |
|||
| Nov. 5, 2020 | |||
Sage Therapeutics (SAGE) is a commercial stage biotechnology company specializing in therapies for brain disorders.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| BIIB |
| BMY |
| CLDX |
| DRNA |
| EPZM |
| GILD |
| GLYC |
| INO |
| IONS |
| ISRG |
| MCHP |
| MRNA |
| PLX |
| REGN |
| SGEN |
| VBLT |
| VSTM |
| XLNX |
| XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2020 William P. Meyers